Coronary Artery Disease

Novel percutaneous adventitial drug delivery system for regional vascular treatment

  1. Fumiaki Ikeno MD1,
  2. Jennifer Lyons RVT1,
  3. Hideaki Kaneda MD, PhD1,
  4. Muhammad Baluom PhD2,
  5. Leslie Z. Benet PhD2,
  6. Mehrdad Rezaee MD, PhD1,*

Article first published online: 23 SEP 2004

DOI: 10.1002/ccd.20167

Issue

Catheterization and Cardiovascular Interventions

Catheterization and Cardiovascular Interventions

Volume 63, Issue 2, pages 222–230, October 2004

Additional Information

How to Cite

Ikeno, F., Lyons, J., Kaneda, H., Baluom, M., Benet, L. Z. and Rezaee, M. (2004), Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheterization and Cardiovascular Interventions, 63: 222–230. doi: 10.1002/ccd.20167

Author Information

  1. 1

    Cardiovascular Medicine, Stanford University Medical Center, Stanford, California

  2. 2

    Department of Biopharmaceutical Sciences, University of California, San Francisco, California

*Stanford University Medical Center, 300 Pasteur Drive, RM H2-103, Stanford, CA 94305

Publication History

  1. Issue published online: 23 SEP 2004
  2. Article first published online: 23 SEP 2004
  3. Manuscript Accepted: 26 MAY 2004
  4. Manuscript Received: 24 JUL 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (597K)

Keywords:

  • adventitial;
  • restenosis;
  • drug delivery;
  • coronary artery disease;
  • myocardium

Abstract

A novel intracoronary microsyringe system (MicroSyringe) was developed for regulated drug injection into the adventitial space. In this report, the feasibility, safety, and distribution pattern of vascular treatment with this modality were tested in 17 swine by delivering Oregon green-labeled paclitaxel (OGP) and tacrolimus. Coronaries were harvested 0.5–96 hr postinjection and analyzed for drug by fluorescence histochemistry (OGP) and liquid chromatography-mass spectrometry (tacrolimus). Histopathological analysis was subsequently performed. The microsyringe deliveries were performed safely in all cases. In the OGP-injected group, within 2 hr postprocedure there was intense staining of the adventitia, media, and endothelium around the injection site, and by 23 hr staining extended distally by 27.5 mm. With tacrolimus, similar longitudinal drug distribution was seen; furthermore, by 48 hr there was detectable drug over 40 mm proximal and distal to the injection site. Significant levels of tacrolimus were detectable in coronaries at 96 hr. Percutaneous adventitial delivery is safe, feasible, and provides consistent dosing for complete treatment of a vascular territory. Catheter Cardiovasc Interv 2004;63:222–230. © 2004 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (597K)